Data from the DALIAH trial,22 a phase three randomized controlled trial of IFN‐α (including IFNα‐2a and IFNα‐2b) versus hydroxyurea (HU) in MPN patients, brought to light the most important information in this regards up to date. The gene discussed is IFNA2; the disease is myeloproliferative neoplasm.